

# MazEF-rifampicin interaction suggests a mechanism for rifampicin induced inhibition of persisters

**Cyrus Alexander**

Institute of Life Sciences, Bhubaneswar

**Ankeeta Guru**

Institute of Life Sciences, Bhubaneswar

**Pinkilata Pradhan**

Institute of Life Sciences, Bhubaneswar

**Sunanda Mallick**

Institute of Life Sciences, Bhubaneswar

**Nimai Charan Mahanandia**

National Dairy Research Institute

**Bharat Bhushan Subudhi**

Siksha O Anusandhan University School of Pharmaceutical Sciences

**Tushar Kant Beuria** (✉ [tkbeuria@ils.res.in](mailto:tkbeuria@ils.res.in))

Institute of Life Sciences, Bhubaneswar <https://orcid.org/0000-0003-3352-4508>

---

## Research article

**Keywords:** TA system, MazEF, Rifampicin, Bacterial persistence.

**Posted Date:** October 14th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-35194/v3>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on October 27th, 2020. See the published version at <https://doi.org/10.1186/s12860-020-00316-8>.

# Abstract

**Background:** Persistence is a natural phenomenon whereby a subset of a population of isogenic bacteria either grow slow or become dormant conferring them with the ability to withstand various stresses including antibiotics. In a clinical setting bacterial persistence often leads to the recalcitrance of various infections increasing the treatment time and cost. Additionally, some studies also indicate that persistence can also pave way for the emergence of resistant strains. In a laboratory setting this persistent phenotype is enriched in nutritionally deprived environments. Consequently, in a batch culture the late stationary phase is enriched with persistent bacteria. The mechanism of persister cell formation and its regulation is not well understood. Toxin-antitoxin (TA) systems have been implicated to be responsible for bacterial persistence and rifampicin is used to treat highly persistent bacterial strains. The current study tries to explore a possible interaction between rifampicin and the MazEF TA system that furthers the former's success rate in treating persistent bacteria.

**Results:** In the current study we found that the population of bacteria in the death phase of a batch culture consists of metabolically inactive live cells resembling persisters, which showed higher membrane depolarization as compared to the log phase bacteria. We also observed an increase in the expression of the MazEF TA modules in this phase. Since rifampicin is used to kill the persisters, we assessed the interaction of rifampicin with MazEF complex. We showed that rifampicin moderately interacts with MazEF complex with 1:1 stoichiometry.

**Conclusion:** Our study suggests that the interaction of rifampicin with MazEF complex might play an important role in inhibition of persisters.

## Background

Persisters represent a subset of a population of isogenic bacteria that are characterized by reduced or no growth, thereby helping the bacterial population tide over stressful situations including antibiotics (1). Upon removal of the stress, these persister cells can go back to their normal growth and functioning without any acquired resistance. Whether they stochastically exist in the population as an insurance or is an induced phenotype to the stress, they play a key role in re-establishing many infections (2). Apart from antibiotics, lack of nutrients is a major stress for the exponentially growing bacteria (3). The number of persisters increase significantly during the late log and stationary phase when there is lack of nutrients (4, 5). In a batch culture, the late stationary phase cultures showed increased persistence to various antibiotics which suggests that the late stationary phase bacteria behave as natural persisters. Although the mechanism of persister formation is not fully understood, the link between toxin-antitoxin (TA) modules and persisters formation is well recognized (6). TA systems are ubiquitously present in all prokaryotes, which regulate several aspects of cell growth and survival strategies. In prokaryotes, TA systems consists of a stable toxin and a labile antitoxin. One of the well-studied TA modules in *E.coli* is the MazEF system. MazEF is a Type II TA system where MazE, an antitoxin, neutralizes MazF toxin, an endoribonuclease. Studies suggest that MazEF plays a significant role in bacterial persistence. Although

the deletion or the over expression of the MazEF does not induce persister formation, (7, 8) the over expression of MazF alone induces the persister formation (7, 9). Similarly, ClpP and Lon proteases, which degrade MazE, when deleted led to the decrease in persister population (9).

Bacterial persistence makes cells antibiotic tolerant which is a threat for disease control. This phenomenon has been widely studied in case of *Mycobacterium tuberculosis* where persisters comprise a larger population (10). Rifampicin, a semi-synthetic broad-spectrum antibiotic, is used to treat persistent mycobacteria. It is recently reported that high doses of rifampicin not only clears the persisters and shortens the treatment time, but also prevents the relapse of tuberculosis (11, 12). The above observations led us to investigate the correlation between the stationary phase persisters with MazEF expression and the effects of rifampicin. In this study we showed that MazEF expression is induced during the late phase of bacterial growth and rifampicin directly interacts with MazEF complex. For the first time we showed the interaction of rifampicin with a TA module.

## Results

### ***E. coli* death phase population consists of live cells that are metabolically inactive.**

In a batch culture, a typical bacterial growth curve consists of 5 distinct phases, i.e., lag phase, exponential phase, stationary phase, death phase and finally followed by a long-term stationary phase that is maintained for years (13). The death phase in the growth curve has been considered for a long time as a stochastic event. When the cultural environment can no longer support the growth due to its limited resources in terms of nutrition, space and steady build-up of toxic metabolites, it causes cell death. When we examined cells from different stages of the growth curve, we observed a sharp decrease in the ability of *E.coli* to form colonies by 72 hours (Fig. 1A). However, we did not notice any substantial increase in the dead cell population (Fig. 2A). We observed that by 72 hours there was an approximate 95 % drop in the ability of *E. coli* to grow in a LB agar plate (Fig. 1A). Whereas, when the same population was observed under microscope after staining with a live-dead stain, almost all the cells stained green, showing live cells (Fig. 2A). To further negate that the decrease in the colony forming units (cfu) was not due to the decrease in the actual cell numbers, we calculated the total number of cells by measuring the scattering at 600 nm (OD<sub>600</sub>) and counting the number of cells using a flow cytometer. The results showed an initial increase in the total relative cell counts till 40 hrs which remained unchanged until 96 hrs (Fig. 1C & D). We also found that the steady state *E. coli* was not affected by ampicillin, whereas, can be inhibited by rifampicin (Fig. S1). We determined the metabolic activity of the bacterial cells at various time points (Fig. 1B). The result showed an increase in the metabolically active cells until 40 hrs, which then decreased to near zero by 72 hrs. This data correlated with the cfu count data. Hence, we conclude that the death phase population of the *E.coli* growing in a batch culture mainly consisted of live cells with reduced metabolic activity, and have lost their ability to grow on solid LB agar plates.

### ***E. coli* death phase population does not show hallmarks of apoptosis.**

Historically the death phase in a batch culture has been considered to be mainly comprised of dead or dying cells. Due to nutrient and space limitations the cells can no longer grow and eventually stochastically die (14). However, recent evidences suggest that programmed cell death may be a viable strategy in prokaryotes (15-17). So, with this initial assumption we wanted to shed light on the mode of death during bacterial death phase. To prove this, we checked for the presence of two well characterized apoptotic markers i.e. Phosphatidylserine (PS) exposure and DNA fragmentation, at various stages of growth in a batch culture. It has been shown earlier that bacteria when exposed to antibiotics test positive for these markers showing apoptotic like death (18). However, the late stationary phase cells and the death phase cells did not show any increase in either PS exposure or DNA fragmentation (Fig. 3A &B). Interestingly, we also did not see an increase in cells stained with propidium iodide which indicates the lack of dead cells in the bacterial death phase. These results corroborate our initial finding that the death phase population mainly comprise of live cells which have lost their ability to grow on LB agar plates. As a positive control we used kanamycin treated cells and they showed an increase in the propidium iodide and PS exposure (Fig. 3A)

### **Loss in membrane polarity in the later stages of a batch culture indicates increase in persistent phenotype.**

The cell membrane in bacteria is a semipermeable membrane that protects the cell from many outer stresses including antibiotics. All living cells inherently and actively maintain a potential difference across its membrane thereby generating a membrane potential (19). It is now known that the membrane potential is responsible for a wide range of signalling and processing. From pH homeostasis to cell division and even environmental sensing the bacterial membrane potential is dynamic tool (20). Many antibacterial compounds achieve their goal by altering the membrane potential of the cell. Recent reports showed that some antibiotics can induce membrane depolarization and kill bacteria (21-23). Alternatively, it is also shown that mild increases in membrane depolarization achieved by the cell itself in response to stresses can promote persister formation (24, 25). We observed that *E. coli* grown in a batch culture tend to mildly increase its membrane potential in the whole population at different time points (6 hrs – 72 hrs) (Fig. 3C). This supported the idea that the persister formation in steady state and death phase might have increased due to change in membrane potential.

### **Expression of the MazEF-TA modules increases overtime in a batch culture of the *E. coli*.**

The role of the TA modules in the bacteria is highly debatable. There are reports that suggest TA modules play an important role during bacterial programmed cell death, whereas, others advocate their roles during persister formation. Several type II TA modules are known to induce the persister formation in various bacteria. For example, overexpression of several toxins (i.e., TisB, HokB, etc.) reportedly increases the number of persister formation, whereas, deletion of the toxins decrease the number of persistent cells (26-28). MazEF is one of the TA module that has been extensively studied and several reports support their role in the persister formation in different bacteria (9, 29, 30). In *E. coli*, the MazF expression leads to growth arrest and enhance its survivability against various stresses (9, 31). To understand the role of

different TA modules during the death phase of the *E. coli*, we quantified the expression of MazEF along with five other Type-II TA modules (ChpBK/S, HicAB, MsqRA, RelEB, YoeB/YefM) using qRT-PCR. Our result showed that the expression of all the tested TA modules increased with increasing time (**Fig. 2B & Fig. S2**). Compared to the log phase (6 hrs) bacteria, the amount of MazEF increased nearly 2 folds in the steady state (48 hrs) and the death phase (72 hrs). Compared to the log phase, the number of persisters are reported to be higher during the steady state and the death phase of bacteria. Thus, our finding suggests that the higher MazEF expression may be related to higher persister formation in *E. coli*. As the MazEF TA system is well regarded as one of the factors responsible for the persister formation, we further focused our study to understand its interaction with rifampicin, a persister modulator.

### **Rifampicin directly interacts with the MazEF complex.**

Persisters can tolerate antibiotics not by acquiring any resistance, but through slowing down their metabolism. The activation of MazEF-TA module increases the number of persisters, whereas, bacteria lacking MazF becomes more susceptible to antibiotics (27, 30). These observations suggested that targeting MazEF may provide a clue to target the persisters. To identify the molecules that can interact with the MazEF complex and inhibit bacterial growth, we performed molecular docking of MazEF complex, MazE or MazF with molecules from an FDA approved drug library containing 800 drug molecules. The 10 best ranked drugs against MazE, and MazF are shown in (**Supplementary Table 1**). Further analysis of the molecular docking data revealed that rifampicin has higher affinity (-8.3 Kcal/mol) for MazE structure than MazF (-6.2 Kcal/mol). In agreement with this data, rifampicin was found to bind in the deep pocket of MazE (**Fig. 4A**), whereas, for MazF it shows interaction on the surface (**Fig. 4B**). The molecular docking of rifampicin was carried out against the MazEF complex (PDB ID: 1UB4, chain A and C). As shown in the figure, rifampicin is predicted to preferentially interact in the same cavity of MazE (**Fig. 4C**). The *in-silico* data suggested that among the screened molecules rifampicin has a strong affinity against MazEF complex. Rifampicin is an antibiotic used for treatment of tuberculosis where persistence is a major problem. It is known to induce antibiotic tolerance in mycobacteria and higher dose can kill the persisters and reduce the duration of the treatment (11, 32).

To confirm the direct interaction of MazEF with rifampicin, we purified the MazEF complex (**Fig. S3**) and performed the interaction studies with rifampicin using fluorescence binding assay. We used two different ways to determine the interaction between MazEF and rifampicin. First, intrinsic tryptophan fluorescence was used to determine the MazEF-rifampicin interaction. The result showed that rifampicin interacts moderately with MazEF complex with a dissociation constant of  $42 \pm 8$  mM (**Fig. 5A**). Second, MazEF was labelled with a hydrophobic fluorescent dye Bis-ANS and the change in Bis-ANS fluorescence on addition of rifampicin was used to determine the MazEF-rifampicin interaction. Our result showed a dissociation constant of  $12.9 \pm 4.7$  mM for MazEF-rifampicin complex (**Fig. 5B**). Both the results indicated moderate interaction of rifampicin to the MazEF complex. We further determined the stoichiometry of MazEF-rifampicin complex using Job's continuous variation method (**Fig. 5C**). Our result showed that rifampicin interacts with MazEF with a stoichiometry of 1:1. To verify that the interaction of rifampicin with MazEF complex is a specific one, we determined the interaction of ampicillin with MazEF

complex. Ampicillin did not affect the persister formation and was previously used by several researchers to kill the normal bacteria and enrich the persisters. Interestingly, our *in-silico* data showed that ampicillin does not interact with the MazE. The affinity of ampicillin with MazE was calculated to be -6.4 Kcal/mol which is much lower as compared to the interaction between rifampicin-MazEF complex (-8.3 Kcal/mol). Similarly, fluorescence binding assay did not show any significant change in the fluorescence of MazEF complex when titrated against ampicillin, suggesting that ampicillin does not interact with MazEF complex (data not shown).

## Discussion And Conclusion

Although bacterial persistence is one of the main reasons for recalcitrance of various infections, its importance was acknowledged on par with bacterial resistance relatively recently (33). The major difference between antibacterial resistance and persistence is that the antibacterial resistance is caused by a heritable trait that is spontaneously generated giving rise to mutants that can actively neutralize a given threat. While persistence represents a subset of the microbial population that is either dormant or slow growing there by ensuring that a part of the population survives a given catastrophic event (34). On the return of favourable conditions these dormant bacteria can grow and re-establish the original population which is susceptible to the original stress. The mechanism by which isogenic bacteria achieve such a reversible persistent state is not fully understood. Yet evidences suggest that persistence may be the end result of stochastic activation of toxins from toxin-antitoxin systems present in microbes. The TA systems represent genetic loci that code for a protein toxin that can cause growth arrest by interfering with essential cellular processes, and a corresponding antitoxin that is co-expressed that neutralizes the toxin (35). The antitoxin has a lower stability as compared to the toxin and consequently has a high turn-over rate. Conditions that prevent the antitoxin production or accelerate its degradation can thus activate the toxin. Similarly, conditions that favours antitoxin production, stability or the degradation of the toxin may prevent persister formation. The MazEF TA system is one of the well-studied Type II TA systems in *E.coli* and has been linked to cause persistence upon activation. The ectopic overexpression of MazF in *E.coli* causes growth arrest and this dormancy can be reversed by ectopically over-expressing the antitoxin MazE (7). This reversibility of dormancy is time bound as beyond the “point of no-return” the toxin becomes too toxic for the cell (36). In addition to antibacterial stresses, nutritional stress can also lead to the formation of persisters (3). In stationary phase bacteria nearly 1 % of the cells comprise of persisters which makes it difficult to be treated by any antibiotics (3). Our study showed that bacteria present in the steady state or death phase in a batch culture majorly consisted of live but metabolically inactive cells, which have lost their ability to form colonies on nutrient agar plates. These bacterial population also did not show any apoptotic markers that are commonly shown by bacteria when treated with antibiotics. This suggests that the death phase cells from the bacterial culture are morphologically and functionally different from the dying bacterial cells treated with antibiotics. We also observed an increase in the MazEF TA modules in these late stationary phase and death phase bacteria. These bacterial populations were also resistant towards ampicillin, but sensitive to rifampicin suggesting their resemblance with the persisters (Fig. S1). Our *In-silico* and biochemical experiments showed that MazEF

interacts directly with rifampicin, a commonly used antibiotic against persisters, with moderate affinity. We further showed that the stoichiometry of the MazEF-rifampicin complex is 1:1. It is currently known that rifampicin acts by interacting with bacterial DNA dependent RNA polymerase and inhibiting its function (37). This interaction of rifampicin with RNA polymerase is very strong ( $K_d = 1 \text{ nM}$  at  $37 \text{ }^\circ\text{C}$ ) (38) and thus a low amount of rifampicin should be able to kill bacteria. Likewise, the recommended dosage of rifampicin is  $10 \text{ mg/kg}$ , however, this dosage is not sufficient to kill the persisters (11). Several studies have suggested that MazEF complex plays a major role during persister formation (9). In the presence of antibiotics or other stress, MazF expression induces reversible persister formation which can regrow once the antitoxin MazE is being synthesized and sequesters MazF (31). Recent reports showed that high dose of rifampicin ( $100 \text{ }\mu\text{g/mL}$ ) is not only able to kill the persisters, but also reduces the treatment duration and prevents disease relapse in *Mtb* (11). Our results showed that the rifampicin at this concentration interacts with MazEF complex. Overall, our study suggests that the interaction of rifampicin with MazEF might play a role to inhibit persister formation. However, a detailed study is required for a better understanding of the system.

## Methods

**Growth conditions and growth curve:** The growth curve was monitored using standard procedure mentioned earlier (39). Briefly, *E. coli* MG1655 (WT) was streak plated onto LB-agar nutrient plate and incubated at  $37 \text{ }^\circ\text{C}$  for 12-15 hours. A single colony was inoculated in  $50 \text{ mL}$  LB broth and grown overnight at  $37 \text{ }^\circ\text{C}$  and  $200 \text{ rpm}$ . From the above culture  $100 \text{ }\mu\text{L}$  was transferred to fresh  $250 \text{ mL}$  of LB broth in  $500 \text{ mL}$  flasks and allowed to grow at  $37 \text{ }^\circ\text{C}$  and  $200 \text{ rpm}$ . Samples were collected at various time points and were used for various experiments as described below. The total number of cells at each time points was monitored by  $\text{OD}_{600}$  and flow cytometric cell count. To determine the viable cell count, cells were spread on LB agar plates and incubated at  $37 \text{ }^\circ\text{C}$  for 12-15 hours. The lowest dilution with more than 30 colonies was considered for viable cell counts.

**Metabolic state of *E. coli* MG1655 at various stages of growth:** *E. coli* MG1655 was grown in  $250 \text{ mL}$  LB-broth as mentioned earlier. Samples were collected at various time points and added to an opaque walled 96-well plate. An equal volume of BacTiter-Glo™ reagent was added as per manufacturer's instructions, incubated for 5 minutes and luminescence was measured using an ELISA plate reader. The luminescence is directly proportional to the total ATP content which is representative of the metabolic state of cells.

**Live-Dead Assay and Microscopy:** *E. coli* MG1655 was grown in  $250 \text{ mL}$  LB-Broth as mentioned earlier.  $1 \text{ mL}$  samples were collected at various time points and centrifuged at  $10,000 \text{ }g$  for  $10 \text{ min}$ . All samples were washed with  $0.85 \text{ \% NaCl}$  twice and resuspended in the same and the  $\text{OD}_{600}$  was adjusted to  $0.1$ . Again, all samples were diluted 1:10 with  $0.85 \text{ \% NaCl}$  to a final volume of  $1 \text{ mL}$ . To determine the live dead status of the culture, BacLight Bacterial viability kit (Invitrogen) was used. The kit uses SYTO9 (green) to visualize live cells and propidium iodide (red) to visualize the dead cells. A 1:1 mixture of SYTO9-PI reagent ( $3 \text{ }\mu\text{L}$ ) was added to  $1 \text{ mL}$  of diluted sample, incubated for 15 minutes at room

temperature. Slides were prepared and samples were observed under fluorescence microscope (Olympus BX51) as described previously (40).

**Detection of Phosphatidylserine and Membrane compromise:** *E.coli* MG1655 was grown as stated above, samples were collected at various time points and washed twice with 1X PBS pH 7.2. The cells were then diluted in 1 X annexin V binding buffer to a concentration of one million cells/mL. Cells were stained by annexin V and propidium iodide as recommended by the kit manufacturer. The cells were incubated for 15 minutes in the dark and then acquired using BD FACS Calibur and results were analysed using FlowJo™ V 10 software.

**Membrane Depolarization Assay:** *E.coli* MG1655 was grown as stated above and samples were collected at various time points. 20 µL of sample from each time point was added to 200 µL reaction mixture containing 0.85 % NaCl and 20 µL of DiBAC<sub>4</sub> (100 µg/mL + 0.5% Tween 20) and incubated at 25 °C for 30 min in the dark. The fluorescence intensity was determined using BD FACS Calibur and the results were analyzed using FlowJo™ V 10 software.

**DNA Fragmentation Assay:** *E.coli* MG1655 was grown as mentioned earlier and samples were collected at various time points. The samples were fixed with 1 % paraformaldehyde for 30 min on ice. They were then washed with 0.85 % NaCl twice and resuspended in ice cold 70 % ethanol and stored at -20 °C till the day of experiment. To observe the DNA fragmentation profile during different stages of growth, samples were stained with APO-BrdU™ TUNEL assay kit and data acquired using Beckman Coulter Cytoflex-S and results were analysed using FlowJo™ V 10 software.

**Quantification of TA systems at various time points using qRT-PCR:** RNA was isolated from the cells collected at different time points using Qiagen RNeasy RNA isolation kit and cDNA library was prepared. Then qRT-PCR was performed to quantify the relative abundance of mRNA of various toxins and antitoxins.

**In silico screening of MazEF interacting molecules.** The structure of MazEF complex with PDB ID: 1UB4 was selected as the target. For MazE, and MazF, the chain A and C was used. Drugs from FDA approved library were screened against these targets using the Autodock Vina program and ranked based on their binding affinities for these targets. Rifampicin has good ranks against both targets and thus selected for molecular docking using the Autodock Vina program and analysed using the PyMol program (41).

**Purification of MazEF complex:** Purification of MazEF complex was carried out using standard procedure with some modifications (42). The detailed procedure is mentioned in Supplementary method section (Fig. S3, SM1).

**Fluorescence interaction studies:** The interaction between MazEF and rifampicin was determined by fluorescence assay using the procedure mentioned earlier with few modifications (43). We used both intrinsic tryptophan fluorescence and Bis-ANS labelling to determine the dissociation constant. First, purified MazEF (1 µM) was titrated against increasing concentrations of rifampicin (5-100 µM). The

tryptophan emission fluorescence spectra (310 – 400 nm) was monitored for an excitation wavelength of 285 nm. The change in fluorescence intensity at 340 nm was used to determine the equilibrium dissociation constant using a double reciprocal plot. Second, MazEF was labelled with Bis-ANS by incubating the protein with 10 folds higher molar concentration of Bis-ANS dye in 50 mM Tris buffer, pH 8 containing 150 mM NaCl for 1 hr at 4 °C. The reaction mixture was dialyzed overnight in 25 mM HEPES buffer (pH 7.4) containing 50 mM NaCl. The labelled MazEF (1 µM) was titrated against increasing concentrations of rifampicin (1-100 µM) and the Bis-ANS emission fluorescence spectra (400 – 600 nm) was monitored for an excitation wavelength of 380 nm. The change in fluorescence intensity at 495 nm was used to determine the equilibrium dissociation constant using a double reciprocal plot. The stoichiometry of MazEF and rifampicin was assessed using Job's method of continuous variation. Then the change in Bis-ANS-MazEF fluorescence was observed with increasing the rifampicin concentration and decreasing the protein concentration while keeping the total concentration constant at 1 µM. This change in fluorescence intensity was used for Job's plot.

## Abbreviations

**TA:** Toxin-antitoxin

**WT:** Wild-type

**cfu:** Colony forming units

**PS:** Phosphatidylserine

**PI:** Propidium iodide

## Declarations

**Ethics approval and consent to participate:** Not applicable

**Consent for publication:** Not applicable

**Availability of data and material:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** This work was supported by grants from Department of Science and Technology, Govt. of India, Science & Engineering Research Board (SERB), India [EMR/2016/006831] and core funding from Institute of Life Sciences, Bhubaneswar to TKB. CA and SM were supported by a senior research fellowship from Institute of Life Sciences, Bhubaneswar, India. AG was supported by a senior research fellowship from Inspire. PP was supported by a junior research fellowship from University Grants Commission, India. The

funding bodies played no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

**Authors' contributions:** CA, AG and PP planned and performed all the experiments. SM purified the protein and discussed the results. NCM and BBS performed the computational experiments and analysis. CA, BBS and TKB performed the analysis, discussed the results and wrote the manuscript. All authors have read and approved the manuscript.

**Corresponding author:** Correspondence to Tushar Kant Beuria

**Acknowledgements:** We thank Satish Devadas and Punit Prasad for their suggestions for analysis of flow cytometry data. We thank Neera Singh for editing of the manuscript.

**Authors' information:**

### **Affiliations**

**Infectious Disease Biology, Institute of Life Sciences, Nalco Square, Bhubaneswar, India.**

Cyrus Alexander, Ankeeta Guru, Pinkilata Pradhan, Sunanda Mallick and Tushar Kant Beuria

**Manipal Academy of Higher Education, Manipal, Karnataka, India.**

Cyrus Alexander and Sunanda Mallick

**Regional Centre for Biotechnology, Faridabad, Haryana, India.**

Ankeeta Guru and Pinkilata Pradhan

**Animal Biotechnology Centre, National Dairy Research Institute, Karnal, Haryana, India.**

Nimai Charan Mahanandia

**Drug Development and Analysis, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar, India.**

Bharat Bhushan Subudhi

## **References**

1. Miyaue S, Suzuki E, Komiyama Y, Kondo Y, Morikawa M, Maeda S. Bacterial Memory of Persisters: Bacterial Persister Cells Can Retain Their Phenotype for Days or Weeks After Withdrawal From Colony-Biofilm Culture. *Front Microbiol.* 2018;9:1396.
2. Wood TK. Strategies for combating persister cell and biofilm infections. *Microbial biotechnology.* 2017;10(5):1054-6. Epub 2017/07/12.

3. Wood TK, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy. *Applied and environmental microbiology*. 2013;79(23):7116-21. Epub 2013/09/17.
4. Keren I, Minami S, Rubin E, Lewis K. Characterization and transcriptome analysis of *Mycobacterium tuberculosis* persisters. *mBio*. 2011;2(3):e00100-11.
5. Haurlyuk V, Atkinson GC, Murakami KS, Tenson T, Gerdes K. Recent functional insights into the role of (p)ppGpp in bacterial physiology. *Nat Rev Microbiol*. 2015;13(5):298-309.
6. Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. *Nat Rev Microbiol*. 2017;15(8):453-64.
7. Fu Z, Tamber S, Memmi G, Donegan NP, Cheung AL. Overexpression of MazFsa in *Staphylococcus aureus* induces bacteriostasis by selectively targeting mRNAs for cleavage. *Journal of bacteriology*. 2009;191(7):2051-9. Epub 2009/01/27.
8. Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, et al. Persister formation in *Staphylococcus aureus* is associated with ATP depletion. *Nat Microbiol*. 2016;1:16051.
9. Tripathi A, Dewan PC, Siddique SA, Varadarajan R. MazF-induced growth inhibition and persister generation in *Escherichia coli*. *The Journal of biological chemistry*. 2014;289(7):4191-205. Epub 2014/01/01.
10. Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. *Antimicrobial agents and chemotherapy*. 2012;56(5):2223-30. Epub 2012/03/07.
11. Hu Y, Liu A, Ortega-Muro F, Alameda-Martin L, Mitchison D, Coates A. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. *Frontiers in microbiology*. 2015;6:641. Epub 2015/07/15.
12. Liu Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, Harrison T, Davies G, et al. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. *J Antimicrob Chemother*. 2018;73(3):724-31.
13. Finkel SE. Long-term survival during stationary phase: evolution and the GASP phenotype. *Nature reviews Microbiology*. 2006;4(2):113-20. Epub 2006/01/18.
14. Watson SP, Clements MO, Foster SJ. Characterization of the starvation-survival response of *Staphylococcus aureus*. *Journal of bacteriology*. 1998;180(7):1750-8. Epub 1998/04/16.
15. Allocati N, Masulli M, Di Ilio C, De Laurenzi V. Die for the community: an overview of programmed cell death in bacteria. *Cell death & disease*. 2015;6:e1609. Epub 2015/01/23.
16. Engelberg-Kulka H, Amitai S, Kolodkin-Gal I, Hazan R. Bacterial programmed cell death and multicellular behavior in bacteria. *PLoS genetics*. 2006;2(10):e135. Epub 2006/10/31.
17. Peeters SH, de Jonge MI. For the greater good: Programmed cell death in bacterial communities. *Microbiological research*. 2018;207:161-9. Epub 2018/02/21.
18. Dwyer DJ, Camacho DM, Kohanski MA, Callura JM, Collins JJ. Antibiotic-induced bacterial cell death exhibits physiological and biochemical hallmarks of apoptosis. *Molecular cell*. 2012;46(5):561-72. Epub 2012/05/29.

19. Stratford JP, Edwards CLA, Ghanshyam MJ, Malyshev D, Delise MA, Hayashi Y, et al. Electrically induced bacterial membrane-potential dynamics correspond to cellular proliferation capacity. *Proc Natl Acad Sci U S A*. 2019;116(19):9552-7.
20. Benarroch JM, Asally M. The Microbiologist's Guide to Membrane Potential Dynamics. *Trends in microbiology*. 2020;28(4):304-14. Epub 2020/01/19.
21. Cheng M, Huang JX, Ramu S, Butler MS, Cooper MA. Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2014;58(11):6819-27.
22. Te Winkel JD, Gray DA, Seistrup KH, Hamoen LW, Strahl H. Analysis of Antimicrobial-Triggered Membrane Depolarization Using Voltage Sensitive Dyes. *Front Cell Dev Biol*. 2016;4:29.
23. Morin N, Lanneluc I, Connil N, Cottenceau M, Pons AM, Sable S. Mechanism of bactericidal activity of microcin L in *Escherichia coli* and *Salmonella enterica*. *Antimicrob Agents Chemother*. 2011;55(3):997-1007.
24. Wang T, El Meouche I, Dunlop MJ. Bacterial persistence induced by salicylate via reactive oxygen species. *Sci Rep*. 2017;7:43839.
25. Verstraeten N, Knapen WJ, Fauvart M, Michiels J. Membrane depolarization-triggered responsive diversification leads to antibiotic tolerance. *Microb Cell*. 2015;2(8):299-301.
26. Dorr T, Vulic M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in *Escherichia coli*. *PLoS Biol*. 2010;8(2):e1000317.
27. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in *Escherichia coli*. *J Bacteriol*. 2004;186(24):8172-80.
28. Kim Y, Wood TK. Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in *Escherichia coli*. *Biochem Biophys Res Commun*. 2010;391(1):209-13.
29. Curtis TD, Takeuchi I, Gram L, Knudsen GM. The Influence of the Toxin/Antitoxin mazEF on Growth and Survival of *Listeria monocytogenes* under Stress. *Toxins (Basel)*. 2017;9(1).
30. Ma D, Mandell JB, Donegan NP, Cheung AL, Ma W, Rothenberger S, et al. The Toxin-Antitoxin MazEF Drives *Staphylococcus aureus* Biofilm Formation, Antibiotic Tolerance, and Chronic Infection. *mBio*. 2019;10(6).
31. Cho J, Carr AN, Whitworth L, Johnson B, Wilson KS. MazEF toxin-antitoxin proteins alter *Escherichia coli* cell morphology and infrastructure during persister formation and regrowth. *Microbiology*. 2017;163(3):308-21. Epub 2017/01/24.
32. Zhu JH, Wang BW, Pan M, Zeng YN, Rego H, Javid B. Rifampicin can induce antibiotic tolerance in mycobacteria via paradoxical changes in *rpoB* transcription. *Nat Commun*. 2018;9(1):4218.
33. Lewis K. Persister cells: molecular mechanisms related to antibiotic tolerance. *Handbook of experimental pharmacology*. 2012(211):121-33. Epub 2012/10/24.
34. Kussell E, Kishony R, Balaban NQ, Leibler S. Bacterial persistence: a model of survival in changing environments. *Genetics*. 2005;169(4):1807-14. Epub 2005/02/03.

35. Unterholzner SJ, Poppenberger B, Rozhon W. Toxin-antitoxin systems: Biology, identification, and application. *Mobile genetic elements*. 2013;3(5):e26219. Epub 2013/11/20.
36. Amitai S, Yassin Y, Engelberg-Kulka H. MazF-mediated cell death in *Escherichia coli*: a point of no return. *Journal of bacteriology*. 2004;186(24):8295-300. Epub 2004/12/04.
37. Wehrli W. Rifampin: mechanisms of action and resistance. *Reviews of infectious diseases*. 1983;5 Suppl 3:S407-11. Epub 1983/07/01.
38. Wehrli W. Kinetic studies of the interaction between rifampicin and DNA-dependent RNA polymerase of *Escherichia coli*. *European journal of biochemistry*. 1977;80(2):325-30. Epub 1977/11/01.
39. Panda P, Taviti AC, Satpati S, Kar MM, Dixit A, Beuria TK. Doxorubicin inhibits *E. coli* division by interacting at a novel site in FtsZ. *Biochem J*. 2015;471(3):335-46.
40. Taviti AC, Beuria TK. MinD directly interacting with FtsZ at the H10 helix suggests a model for robust activation of MinC to destabilize FtsZ polymers. *The Biochemical journal*. 2017;474(18):3189-205. Epub 2017/07/27.
41. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of computational chemistry*. 2010;31(2):455-61. Epub 2009/06/06.
42. Beuria TK, Mullapudi S, Mileykovskaya E, Sadasivam M, Dowhan W, Margolin W. Adenine nucleotide-dependent regulation of assembly of bacterial tubulin-like FtsZ by a hypermorph of bacterial actin-like FtsA. *J Biol Chem*. 2009;284(21):14079-86.
43. Beuria TK, Singh P, Surolia A, Panda D. Promoting assembly and bundling of FtsZ as a strategy to inhibit bacterial cell division: a new approach for developing novel antibacterial drugs. *Biochem J*. 2009;423(1):61-9.

## Figures




Figure 1

Drop in Viability and Metabolic Activity in a Closed Culture. *E. coli* was grown as mentioned earlier and samples were collected at various time point. Viable cell counts and metabolic activity were determined at different time points. Figures shows the viable cell counts (Panel A) and the metabolic activity (Panel B) of the bacteria at different time points. Panel C and D shows the relative cell numbers at different time points determined using OD600 and flow cytometry techniques respectively. All experiments were repeated three times and the graphs represent mean  $\pm$  SEM.




Figure 1

Drop in Viability and Metabolic Activity in a Closed Culture. *E. coli* was grown as mentioned earlier and samples were collected at various time point. Viable cell counts and metabolic activity were determined at different time points. Figures shows the viable cell counts (Panel A) and the metabolic activity (Panel B) of the bacteria at different time points. Panel C and D shows the relative cell numbers at different time points determined using OD600 and flow cytometry techniques respectively. All experiments were repeated three times and the graphs represent mean  $\pm$  SEM.





Figure 2

Live dead staining of bacteria. The live dead staining of *E. coli* at different time points was performed using live dead assay kit and imaging was performed using Olympus BX51 fluorescent microscope (Panel A). The left pane shows the total cells (DIC images), middle pane shows the live cells (green) and the right pane shows the dead cells (red). Expression of MazEF system was monitored at different timepoints for *E. coli* growing in a closed culture using qRT-PCR. Expressions of 16S-rRNA gene was used as control (Panel B). Graphs represents mean+SEM of qRT-PCR data of three independent experiments.





Figure 2

Live dead staining of bacteria. The live dead staining of *E. coli* at different time points was performed using live dead assay kit and imaging was performed using Olympus BX51 fluorescent microscope (Panel A). The left pane shows the total cells (DIC images), middle pane shows the live cells (green) and the right pane shows the dead cells (red). Expression of MazEF system was monitored at different timepoints for *E. coli* growing in a closed culture using qRT-PCR. Expressions of 16S-rRNA gene was used as control (Panel B). Graphs represents mean+SEM of qRT-PCR data of three independent experiments.




Figure 3

*E. coli* death phase does not show apoptotic hall marks. Annexin V/PI was used to determine whether apoptotic like death occurred during the death phase of the bacterial growth curve. *E. coli* at different time points of the growth curve showed no change in the Annexin V/PI labelled cells, whereas, Kanamycin treated showed increased number of Annexin V/PI labelled cells (Panels A). DNA fragmentation pattern (Panel B) and membrane depolarization (Panel C) are shown for cells at different stages of growth in a batch culture. All figures are representative images of three independent experiments.






Figure 3

*E. coli* death phase does not show apoptotic hall marks. Annexin V/PI was used to determine whether apoptotic like death occurred during the death phase of the bacterial growth curve. *E. coli* at different time points of the growth curve showed no change in the Annexin V/PI labelled cells, whereas, Kanamycin treated showed increased number of Annexin V/PI labelled cells (Panels A). DNA fragmentation pattern (Panel B) and membrane depolarization (Panel C) are shown for cells at different stages of growth in a batch culture. All figures are representative images of three independent experiments.




**Figure 4**

In silico and in vitro interaction of MazE/F with Rifampicin. Interaction of MazE/ MazF and MazEF with 800 molecules from FDA approved drug library was performed in silico using molecular docking. The figure shows that rifampicin interacts deep in the cavity with MazE (Panel A) and MazEF complex (Panel C) and not with MazF alone (Panel B). Panel D shows the change in fluorescence intensity with increasing concentrations of rifampicin.




**Figure 4**

In silico and in vitro interaction of MazE/F with Rifampicin. Interaction of MazE/ MazF and MazEF with 800 molecules from FDA approved drug library was performed in silico using molecular docking. The figure shows that rifampicin interacts deep in the cavity with MazE (Panel A) and MazEF complex (Panel C) and not with MazF alone (Panel B). Panel D shows the change in fluorescence intensity with increasing concentrations of rifampicin.



**Figure 5**

In vitro interaction of MazEF with Rifampicin. Panel A shows the change in intrinsic tryptophan fluorescence intensity with increasing concentrations of rifampicin. Panel B shows the change in Bis-ANS fluorescence intensity with increasing rifampicin concentration. The inset in Panel A and B shows the respective double reciprocal plots. Panel C is the Job's plot showing the 1:1 stoichiometry for rifampicin binding to MazEF. All the experiments were performed in triplicates.



**Figure 5**

In vitro interaction of MazEF with Rifampicin. Panel A shows the change in intrinsic tryptophan fluorescence intensity with increasing concentrations of rifampicin. Panel B shows the change in Bis-ANS fluorescence intensity with increasing rifampicin concentration. The inset in Panel A and B shows the respective double reciprocal plots. Panel C is the Job's plot showing the 1:1 stoichiometry for rifampicin binding to MazEF. All the experiments were performed in triplicates.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryMaterial29092020.pdf](#)
- [SupplementaryMaterial29092020.pdf](#)